Clene, Inc. reports significant survival benefits from CNM-Au8® treatment for ALS in recent survival analyses from the HEALEY trial. Clene, Inc. announced promising results from a post hoc analysis of ...
SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the ...
PRESS RELEASEAB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC ...
Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a Michigan Medicine-led study suggests. ALS is a ...
People with higher levels of metals found in their blood and urine may be more likely to be diagnosed with—and die from—amyotrophic lateral sclerosis, or ALS, a University of Michigan-led study ...
With the help of artificial intelligence, a coalition of Bay Area institutions identified 18 FDA-approved drugs that could improve the lives of those suffering from amyotrophic lateral sclerosis, ...
Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a Michigan Medicine-led study suggests. ALS is a ...
Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...
For adults with amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, long-term treatment with tofersen (Qalsody, Biogen) was associated with slowed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results